Forensic Genomics Market By Product and Service (Kits and Reagents, Instruments and Systems, Software and Databases, Forensic Genomics Services); By Application (Criminal Investigation and DNA Databasing, Missing-Person Identification, Unidentified Human Remains Identification, Forensic Genetic Genealogy and Kinship Analysis, Disaster-Victim Identification); By End User (Government Forensic Laboratories, Law-Enforcement Agencies, Private Forensic Laboratories and Service Providers, Medical Examiner and Coroner Offices, Academic and Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Forensic Genomics Market: Database Expansion, Backlog Funding, and Advanced DNA Analysis Reshape Human Identification

The Global Forensic Genomics Market was valued at USD 0.62 billion in 2025 and is projected to reach USD 1.65 billion by 2032, expanding at a CAGR of 15.0% during 2026–2032.

 

Forensic genomics uses advanced DNA analysis to develop investigative leads and establish identity from crime-scene evidence, reference samples, unidentified remains, and family relationships. Forensic Investigative Genetic Genealogy (FIGG) is a specialized part of the field that examines large numbers of Single Nucleotide Polymorphisms through Massively Parallel Sequencing to identify potential genetic relatives. The field relies on extensively validated workflows and strict forensic quality standards. Systems such as Verogen’s MiSeq FGx support high-resolution forensic DNA analysis and NDIS-eligible applications.

 

Routine DNA Workloads Anchor Recurring Market Revenue

Routine crime-laboratory activity remains the market’s largest recurring revenue base because each submission generates demand for collection supplies, extraction reagents, amplification kits, analyzer consumables, interpretation software, laboratory labor, and database services. Criminal casework and DNA databasing together represented an estimated 68% of market revenue, or USD 421.6 million, in 2025. This application segment is projected to grow at a CAGR of approximately 13.2% and exceed USD 1.00 billion by 2032.

The Bureau of Justice Statistics reported that publicly funded U.S. forensic laboratories received approximately 671,000 DNA-databasing requests in 2020 and completed 650,000. These laboratories also received 339,000 forensic-biology casework requests and completed 318,000. Combining the two categories gives approximately 1.01 million requests received and 968,000 completed during the year.

DNA databasing represented 67.1% of the combined completed workload, while forensic-biology casework accounted for 32.9%. The 968,000 completed requests represent the strongest available public measure of recurring U.S. forensic-DNA activity. One investigation can involve multiple samples or submissions, so the figure reflects laboratory workload rather than individuals tested. It also excludes parts of the private and outsourced market, which adds further service demand beyond publicly funded laboratory totals.

Forensic biology was performed by 59% of publicly funded crime laboratories in 2020. Among laboratories handling forensic biology, 97% conducted casework, 94% processed sexual-assault evidence, 46% used probabilistic genotyping, and 44% performed direct-to-DNA analysis. This combination of conventional profile generation and software-based interpretation creates demand across consumables, instruments, analytical platforms, validation services, and training.

 

Backlogs Turn Capacity Shortages into Procurement and Outsourcing

Backlogs are a direct commercial trigger because laboratories must process new evidence while managing older untested samples, analyst shortages, court deadlines, validation work, and database-quality requirements.

At the end of 2020, publicly funded U.S. laboratories reported 121,000 backlogged DNA-databasing requests and 126,100 backlogged forensic-biology requests. Together, these categories represented approximately 247,100 unresolved DNA-related requests. Forensic-biology work accounted for 51.0% of this combined backlog, while DNA databasing represented 49.0%.

Outsourcing has become an important capacity tool. Around 47% of publicly funded crime laboratories outsourced some forensic work in 2020. Among laboratories that outsourced, 71.6% sent out forensic-biology work, while 85.4% of those outsourcing forensic biology outsourced sexual-assault casework. This supports demand for private forensic laboratories, specialist sequencing providers, and service companies able to absorb fluctuating case volumes.

Laboratory and analytical services represented an estimated 25% of the market, or USD 155.0 million, in 2025. The segment is projected to expand at a CAGR of approximately 16.4% to reach USD 448.7 million by 2032 as agencies outsource backlogs, genealogy research, difficult samples, and specialized sequencing work.

Public funding determines how quickly backlogs convert into purchases. The U.S. Bureau of Justice Assistance’s FY2025 DNA Capacity Enhancement for Backlog Reduction program permitted spending on laboratory automation, higher-throughput instruments, procedure validation, capacity expansion, and Rapid DNA implementation. Competitive awards could reach USD 1 million. Such programs create procurement opportunities for automation suppliers, instrument manufacturers, consumables vendors, software providers, and accredited testing laboratories.

Unlike healthcare diagnostics, forensic-genomics purchasing is generally funded through justice budgets, public grants, laboratory operating funds, procurement contracts, and humanitarian programs. Revenue therefore depends heavily on government budget cycles and agency priorities.

 

CODIS Scale Strengthens the U.S. Market

The United States provides the clearest evidence of large-scale forensic-genomics utilization. As of November 2025, the National DNA Index System held more than 19.272 million offender profiles, 6.143 million arrestee profiles, and 1.450 million forensic profiles.

Offender profiles represented approximately 71.7% of these three major profile categories, arrestee profiles accounted for 22.9%, and forensic profiles represented 5.4%. CODIS had generated more than 781,000 hits and assisted more than 758,000 investigations.

These figures show the scale of the infrastructure supporting recurring revenue. New profiles must be generated and reviewed, qualifying records must be uploaded, potential matches require follow-up, and laboratories must maintain compatible chemistries, software, quality-control systems, and trained personnel.

North America accounted for an estimated 43% of global revenue, equivalent to USD 266.6 million in 2025. The regional market is projected to grow at approximately 13.0% annually and reach USD 627.2 million by 2032. Its leading position reflects the scale of CODIS, federal and state funding, established crime-laboratory infrastructure, and early adoption of Rapid DNA and probabilistic-genotyping systems.

The addressable investigative pool is much larger than the number of cases that ultimately reach forensic laboratories. BJS estimated 560,890 rape or sexual-assault victimizations among people aged 12 or older in 2024. Only 23.6% were reported to police, and a smaller proportion led to evidence collection, laboratory submission, testing, and a usable profile.

Homicide creates another important demand pool. The CDC recorded 20,162 U.S. homicide deaths in 2024. These cases can generate crime-scene comparisons, suspect testing, autopsy sampling, kinship analysis, and cold-case review. The number of tests varies because some investigations yield no suitable biological evidence while others involve several samples and repeated analyses.

 

Rapid DNA Extends Testing Beyond Central Laboratories

Rapid DNA systems automate STR profile development and can produce results from a cheek swab in about one to two hours. Their commercial model combines periodic instrument purchases with recurring cartridges, service agreements, training, software, and system integration.

Rapid DNA represented an estimated 14% of the global market, or USD 86.8 million, in 2025. The segment is projected to expand at a CAGR of approximately 18.2% and reach USD 279.8 million by 2032, supported by booking-station deployment, reference-sample processing, disaster response, and the gradual extension of approved casework applications.

The FBI’s July 2026 NDIS procedures list two approved Rapid DNA booking-platform families: the ANDE 6C Series G and the Applied Biosystems RapidHIT ID. This creates a concentrated U.S. approval environment in which vendors with validated platforms can build recurring consumable and support revenue around each installed system.

Rapid DNA adoption depends on more than instrument performance. Booking agencies must coordinate with state CODIS authorities, connect fingerprint and criminal-history systems, apply qualifying-arrest rules, maintain network security, train operators, and comply with state DNA-collection laws.

A larger commercial opening emerged in July 2025 when updated FBI quality standards created a pathway for modified Rapid DNA analysis of eligible forensic casework. Crime-scene use remains tied to accredited CODIS laboratories, approved cartridges, laboratory validation, analyst interpretation, technical review, and applicable quality standards.

Rapid DNA is positioned to complement rather than replace centralized laboratories. Straightforward reference samples and qualifying booking workflows can move closer to the collection point, while mixtures, degraded evidence, low-level DNA, and contested casework continue to require specialist laboratory analysis.

 

Sequencing and Genetic Genealogy Expand the Value of Difficult Evidence

STR profiling retains its leading role because it is standardized, widely validated, and connected to established criminal databases. Advanced sequencing gains value when evidence is degraded, contains mixtures, lacks a direct reference match, or requires relationship analysis across several generations.

NGS, SNP analysis, and forensic genetic genealogy together represented an estimated 17% of global revenue, or USD 105.4 million, in 2025. This is the fastest-growing technology group, with an estimated CAGR of 21.4%, which would raise segment revenue to approximately USD 409.6 million by 2032.

SNP panels use smaller genetic targets and can improve kinship analysis in missing-person and disaster-victim identification. NIST has assessed available SNP sequencing assays according to relationship-prediction performance, cost, processing time, and throughput, reflecting the practical factors agencies consider before adoption.

Forensic genetic genealogy compares genome-wide SNP profiles with accessible genealogy databases and combines genetic relationships with documentary family research. The service is increasingly used in cold cases, unidentified remains, and investigations where conventional STR searches produce no direct match.

Genealogy and advanced kinship applications accounted for an estimated 9% of the market, or USD 55.8 million, in 2025. At a projected CAGR of approximately 21.0%, this application could reach USD 211.9 million by 2032.

These workflows shift spending toward specialist laboratories, sequencing consumables, secure bioinformatics, genealogy research, case-management software, and expert interpretation. Laboratories need reliable sample recovery, validated analysis, secure data handling, statistical interpretation, technical review, and reporting that can withstand legal examination.

The FBI’s NDIS procedures recognize specific sequencing kits and workflows for eligible database submissions, including Verogen’s ForenSeq products and selected mitochondrial DNA applications. This favors suppliers that provide validated end-to-end workflows rather than standalone instruments.

 

Missing Persons and Unidentified Remains Create a Distinct Demand Segment

Missing-person and human-remains programs create demand outside routine criminal casework. These investigations may require direct reference samples, DNA recovered from personal belongings, family-reference samples, mitochondrial DNA, SNP-based kinship analysis, genealogy research, and repeated database searches.

Missing-person and unidentified-remains applications represented an estimated 17% of market revenue, or USD 105.4 million, in 2025. The segment is projected to expand at a CAGR of approximately 17.6% and reach USD 327.9 million by 2032.

The FBI reported 93,447 active missing-person records in NCIC at the end of 2024. It also held 8,546 active unidentified-person records, including 8,267 deceased persons, 44 catastrophe victims, and 235 living individuals unable to establish their identity. During 2024, 647 new unidentified-deceased records were entered.

The global humanitarian need is much larger. Approximately 284,400 missing people were registered by their families with the International Red Cross and Red Crescent Family Links Network at the end of 2024, up around 68% from 2019.

INTERPOL’s international DNA database contains more than 280,000 profiles from 87 countries, including records connected with offenders, crime scenes, missing persons, and unidentified remains. I-Familia contained about 32,000 profiles from 82 countries in April 2026, equal to approximately 11.4% of the broader INTERPOL DNA-profile stock.

Disaster-victim identification accounted for an estimated 6% of the market, equivalent to USD 37.2 million in 2025. Event-driven procurement and international identification programs are expected to support a CAGR of approximately 16.8%, taking the segment to USD 110.3 million by 2032. Large incidents can sharply increase requirements for collection kits, laboratory capacity, kinship testing, portable systems, software, and cross-border data coordination.

 

Revenue Moves Toward Consumables, Software, and Complete Services

The market combines recurring and periodic purchasing models. Consumables formed the largest offering segment, accounting for an estimated 39% of revenue, or USD 241.8 million, in 2025. At an estimated CAGR of 14.2%, consumables revenue is projected to reach USD 612.5 million by 2032.

Recurring revenue comes from extraction and amplification reagents, STR and sequencing kits, Rapid DNA cartridges, capillary-electrophoresis consumables, outsourced casework, genetic genealogy, software support, database operations, validation, training, and quality assurance.

Instruments represented approximately 22% of the market, or USD 136.4 million, in 2025. The segment is projected to grow at a comparatively moderate CAGR of 12.6% to reach USD 313.0 million by 2032 because analyzers, sequencers, robotics, and Rapid DNA platforms have multiyear replacement cycles.

Software and database products accounted for an estimated 14% share, equivalent to USD 86.8 million in 2025. This segment is projected to grow at approximately 18.0% annually and reach USD 275.7 million by 2032 as probabilistic genotyping, genealogy analysis, secure data exchange, and cross-border profile matching become more important.

 

Competition Shifts Toward End-to-End Evidence Workflows

Thermo Fisher Scientific and ANDE hold direct positions in U.S. Rapid DNA booking through the two platform families listed by the FBI. Thermo Fisher also supplies STR kits, analyzers, cartridges, and software, while ANDE focuses on automated platforms and single-use chips for booking, human identification, and field applications. ANDE reports deployments in more than 25 countries.

QIAGEN strengthened its forensic sequencing portfolio through the USD 150 million acquisition of Verogen. QIAGEN expected approximately USD 20 million in Verogen portfolio sales during 2023, compared with about USD 5 million generated through the prior distribution arrangement in 2022. This represented a fourfold increase in revenue associated with the portfolio and reflects the strategic value of integrated sequencing, assays, and bioinformatics.

Promega competes through STR chemistries, DNA preparation and quantification products, and electrophoresis systems. Its PowerPlex 35GY became the first commercially available eight-colour STR kit approved for generating NDIS-eligible profiles in 2025.

Software and specialist-service providers are gaining influence as evidence becomes more complex. STRmix reports use in more than 120 forensic laboratories worldwide. Othram provides forensic genome sequencing, genealogy, kinship analysis, and investigative software. Parabon combines genetic genealogy, kinship analysis, and DNA-based lead generation.

 

Regulation, Workforce, and Privacy Shape Adoption

Forensic-genomics products must meet technical, accreditation, database, and legal requirements. Laboratories must complete validation studies, analyst training, documentation, proficiency testing, and evidence-control procedures before introducing new assays or software.

Europe accounted for an estimated 28% of market revenue, or USD 173.6 million, in 2025 and is projected to expand at a CAGR of approximately 14.0% to reach USD 434.4 million by 2032. The Prüm II Regulation and related 2026 technical arrangements for automated DNA-profile exchange increase demand for compatible data formats, secure infrastructure, validated systems, and standardized quality procedures.

Asia-Pacific represented an estimated 21% share, or USD 130.2 million, in 2025. It is projected to record the fastest regional CAGR of approximately 19.5% and reach USD 453.1 million by 2032 as governments expand forensic laboratories, national DNA databases, missing-person programs, and sequencing capacity.

 

Forensic Genomics Market Trends

Forensic DNA testing is expanding beyond traditional STR profiling toward SNP analysis, massively parallel sequencing and forensic genetic genealogy. These technologies can generate investigative leads from degraded samples, unidentified remains and cases without a direct database match. Their adoption is increasing demand for sequencing systems, DNA extraction products, laboratory automation, bioinformatics software and specialized testing services. Although genomic methods are unlikely to replace STR testing in the near term, they are becoming valuable complementary tools for cold cases and complex investigations. Wider market adoption will depend on lower costs, standardized workflows, trained personnel, validated analytical methods and clear privacy and ethical regulations.

 

Forensic Genomics Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 0.62 Billion
Revenue Forecast in 2032	USD 1.65 Billion
Overall Growth Rate	CAGR of 15.0% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product and Service, By Application, By End User, By Geography
By Product and Service	Kits and Reagents, Instruments and Systems, Software and Databases, Forensic Genomics Services
By Application	Criminal Investigation and DNA Databasing, Missing-Person Identification, Unidentified Human Remains Identification, Forensic Genetic Genealogy and Kinship Analysis, Disaster-Victim Identification
By End User	Government Forensic Laboratories, Law-Enforcement Agencies, Private Forensic Laboratories and Service Providers, Medical Examiner and Coroner Offices, Academic and Research Institutions
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising use of advanced DNA sequencing in forensic investigations, expansion of national DNA databases, growing adoption of forensic genetic genealogy, and increasing demand for human identification in criminal, disaster, and missing-person cases
Customization Option	Available upon request